Real-World Adherence Trajectories of GLP-1 Receptor Agonists Among Adults and Paediatric Patients With Obesity.

Authors

Wenxi Huang, Pareeta Kotecha, Stephen E Kimmel, Richard Segal, Jasmine D Gonzalvo, Angela Marija Pecoski, Davene Wright, Jiang Bian, Steven M Smith, Jingchuan Guo

Published in

Diabetes, obesity & metabolism. Sep 17, 2026. Epub Sep 17, 2026.

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used for obesity treatment, but real-world adherence patterns, particularly among individuals without diabetes and paediatric patients, remain poorly characterised. We aimed to identify 12-month GLP-1 RA adherence trajectories among adults and paediatric patients with obesity without diabetes and to evaluate factors associated with adherence.
We conducted a retrospective cohort study using 2021-2023 MarketScan commercial claims data. Individuals aged ≥ 10 years with obesity without diabetes who initiated GLP-1 RAs were included. Adherence was measured as monthly proportion of days covered (PDC) over 12 months. Group-based trajectory modelling was conducted separately in adult and paediatric cohorts. Multivariable logistic regression was used to identify factors associated with membership in the persistent-user trajectory.
The study included 201 229 adults and 1139 paediatric patients. Five adherence trajectories were identified in each cohort. Among adults, trajectories included immediate discontinuers (19.6%), early discontinuers (23.5%), late discontinuers (20.7%), intermittent adherents (5.5%) and persistent users (30.7%), with mean annual PDC ranging from 0.10 to 0.87. Paediatric trajectory groups were more evenly distributed, with each group representing approximately 18%-22% of the cohort and persistent users comprising 20.3%. Geographic region was consistently associated with adherence, with higher odds of persistent use in the Northeast versus the South among adults (odds ratio [OR], 1.32) and paediatric patients (OR, 1.65).
Most adults and paediatric patients with obesity had suboptimal adherence to GLP-1 RA use over 12 months. Distinct adherence trajectories and consistent regional differences highlight opportunities to better understand and address barriers to long-term obesity pharmacotherapy.

PMID:
42755139
Bibliographic data and abstract were imported from PubMed on 18 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.